LifeStance Health Group (NASDAQ: LFST) has recently received a number of price target changes and ratings updates:
- 8/19/2026 – LifeStance Health Group had its price target raised by BTIG Research from $16.00 to $18.00. They now have a “buy” rating on the stock.
- 8/15/2026 – LifeStance Health Group was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 8/14/2026 – LifeStance Health Group had its price target raised by JPMorgan Chase & Co. from $9.00 to $13.00. They now have a “neutral” rating on the stock.
- 8/11/2026 – LifeStance Health Group was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
- 8/7/2026 – LifeStance Health Group had its price target raised by BTIG Research from $15.00 to $16.00. They now have a “buy” rating on the stock.
- 7/25/2026 – LifeStance Health Group was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 7/24/2026 – LifeStance Health Group had its price target raised by BTIG Research from $12.00 to $15.00. They now have a “buy” rating on the stock.
- 7/21/2026 – LifeStance Health Group had its price target raised by Canaccord Genuity Group Inc. from $11.00 to $13.00. They now have a “buy” rating on the stock.
- 7/14/2026 – LifeStance Health Group had its price target raised by Barclays PLC from $9.00 to $13.00. They now have an “overweight” rating on the stock.
- 7/13/2026 – LifeStance Health Group was downgraded by Zacks Research from “strong-buy” to “hold”.
- 7/13/2026 – LifeStance Health Group had its price target raised by KeyCorp from $11.00 to $13.00. They now have an “overweight” rating on the stock.
- 7/4/2026 – LifeStance Health Group was upgraded by Wall Street Zen from “buy” to “strong-buy”.
Insider Activity
In related news, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the sale, the chief technology officer owned 247,446 shares in the company, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Bessler sold 894,337 shares of LifeStance Health Group stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. The trade was a 62.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,629,850 shares of company stock valued at $154,952,012 in the last quarter. Company insiders own 3.50% of the company’s stock.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Featured Articles
- Five stocks we like better than LifeStance Health Group
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for LifeStance Health Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.
